Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sells $90,232.72 in Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the sale, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. The trade was a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Agios Pharmaceuticals Price Performance

AGIO opened at $35.90 on Friday. Agios Pharmaceuticals, Inc. has a 1 year low of $20.96 and a 1 year high of $62.58. The stock has a 50-day moving average price of $46.77 and a 200-day moving average price of $45.50. The firm has a market cap of $2.05 billion, a PE ratio of 3.16 and a beta of 0.87.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Bank of New York Mellon Corp grew its holdings in shares of Agios Pharmaceuticals by 13.9% during the second quarter. Bank of New York Mellon Corp now owns 223,151 shares of the biopharmaceutical company’s stock valued at $9,622,000 after buying an additional 27,193 shares during the last quarter. TD Asset Management Inc lifted its position in Agios Pharmaceuticals by 34.6% in the 2nd quarter. TD Asset Management Inc now owns 210,472 shares of the biopharmaceutical company’s stock valued at $9,076,000 after acquiring an additional 54,054 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Agios Pharmaceuticals during the 2nd quarter valued at $37,000. Quest Partners LLC bought a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth $40,000. Finally, Headlands Technologies LLC purchased a new position in shares of Agios Pharmaceuticals in the second quarter worth $494,000.

Analysts Set New Price Targets

A number of research analysts have recently commented on AGIO shares. Scotiabank lifted their price target on Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research report on Monday, December 9th. Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Raymond James reaffirmed an “outperform” rating and issued a $51.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Royal Bank of Canada lifted their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $56.33.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.